GPX4 and cancer: Recent studies found that Lenvatinib suppresses GPX4 expression, leading to the accumulation of lipid ROS and ferroptosis.[12b] Ferroptosis is a ROS‐dependent form of cell death that may provide new opportunities for cancer treatment.